Evidence map›Paper›PMID 24855508›Full record

ReviewInternational journal of stem cells2008

Mesenchymal stem cells for treatment of myocardial infarction.

Il-Kwon Ko, Byung-Soo Kim

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of stem cells, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Migration of mesenchymal stem cells to tumor xenograft models andInternational journal of medical sciences · 2018
    Article
  6. Article
  7. Review
  8. Simvastatin improves the homing of BMSCs via the PI3K/AKT/miR-9 pathway.Journal of cellular and molecular medicine · 2016
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Il-Kwon KoDepartment of Bioengineering, Hanyang University, Seoul, Korea.
Byung-Soo KimDepartment of Bioengineering, Hanyang University, Seoul, Korea.
Hanyang University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular diseases including myocardial infarction are one of the major causes of adult mortality. Several treatments such as pharmacological therapy and heart transplantation have been used for the diseases, but the treatments have drawbacks. Therefore, cell-based myocardial therapies have received proper medical attention. Bone marrow stem cell (BMSC) including mesenchymal stem cell (MSC) and hematopoietic stem cell (HSC) is a potential source for cell therapy for heart diseases due to the ability of BMSC to differentiate into cell in cardiac tissue including cardiomyocyte and vascular endothelial cell. This article reviews the use of BMSCs for cardiovascular disease and the differentiation of BMSCs into cardiaomyocytes.

Indexed as

CardiomyocyteDifferentiationMesenchymal stem cellMyocardial infarction

Identifiers

PMID24855508
PMCPMC4021775
OpenAlexW2011847334

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.